FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2012808596> ?p ?o ?g. }

• W2012808596 endingPage "990" @default.
• W2012808596 startingPage "983" @default.
• W2012808596 abstract "Asparaginase comes from different biological sources and the various preparations have different pharmacokinetic properties, and their tendency to induce side-effects is different. Erwinia asparaginase (ASNase) has a shorter half-life than the Escherichia coli preparations, and it has been reported to be less immunogenic than the E. coli preparations and to induce fewer coagulation disorders. Children with newly diagnosed acute lymphoblastic leukaemia (ALL) were included in this study. Twenty-seven patients were treated with Erwinia ASNase (induction therapy 30.000 IU/m2/d i.m. for 10 d, and re-induction therapy 30.000 IU/m2 twice a week for 2 weeks) and 15 were treated with ASNase Medac (induction therapy 1.000 IU/m2/d i.m. for 10 d, and re-induction therapy 5.000 IU/m2 i.m. twice a week for 2 weeks). Blood samples were drawn to determine enzyme activity, l-asparagine, anti-asparaginase antibodies, and coagulation parameters. After i.m. administration, Erwinia ASNase displayed a protracted absorption phase compared to ASNase Medac. The mean bioavailability after i.m. administration was 27% for Erwinia ASNase and 45% for ASNase Medac respectively. Mean trough enzyme activities during induction therapy were Erwinia ASNase 1748 IU/l and ASNase Medac 272 IU/l, and during re-induction therapy Erwinia ASNase 83 IU/l and ASNase Medac 147 IU/l. We conclude that in this setting, therapy with ASNase Medac resulted in sufficient treatment during both phases of therapy, whereas treatment with Erwinia ASNase resulted in unnecessarily intense therapy during the induction phase and insufficient treatment during the re-induction phase. There was no significant difference in the incidence of antibody formation, and therapy with Erwinia ASNase resulted in a more pronounced influence on the coagulation parameters than therapy with ASNase Medac." @default.
• W2012808596 created "2016-06-24" @default.
• W2012808596 creator A5017367890 @default.
• W2012808596 creator A5018939455 @default.
• W2012808596 creator A5025288612 @default.
• W2012808596 creator A5032700341 @default.
• W2012808596 creator A5071720008 @default.
• W2012808596 creator A5074845542 @default.
• W2012808596 creator A5075840216 @default.
• W2012808596 creator A5087936561 @default.
• W2012808596 date "2001-12-01" @default.
• W2012808596 modified "2023-10-17" @default.
• W2012808596 title "Comparison of intramuscular therapy with Erwinia asparaginase and asparaginase Medac: pharmacokinetics, pharmacodynamics, formation of antibodies and influence on the coagulation system" @default.
• W2012808596 cites W135448532 @default.
• W2012808596 cites W1940732706 @default.
• W2012808596 cites W1970593462 @default.
• W2012808596 cites W1990294422 @default.
• W2012808596 cites W1992750424 @default.
• W2012808596 cites W1995905554 @default.
• W2012808596 cites W2005688611 @default.
• W2012808596 cites W2010002712 @default.
• W2012808596 cites W2010064279 @default.
• W2012808596 cites W2034865891 @default.
• W2012808596 cites W2040730344 @default.
• W2012808596 cites W2048017132 @default.
• W2012808596 cites W2056562985 @default.
• W2012808596 cites W2058767848 @default.
• W2012808596 cites W2067667576 @default.
• W2012808596 cites W2074110119 @default.
• W2012808596 cites W2080828049 @default.
• W2012808596 cites W2090525982 @default.
• W2012808596 cites W2133750402 @default.
• W2012808596 cites W2140819149 @default.
• W2012808596 cites W2174610917 @default.
• W2012808596 cites W2341248606 @default.
• W2012808596 cites W426270985 @default.
• W2012808596 doi "https://doi.org/10.1046/j.1365-2141.2001.03148.x" @default.
• W2012808596 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11843837" @default.
• W2012808596 hasPublicationYear "2001" @default.
• W2012808596 type Work @default.
• W2012808596 sameAs 2012808596 @default.
• W2012808596 citedByCount "54" @default.
• W2012808596 countsByYear W20128085962012 @default.
• W2012808596 countsByYear W20128085962013 @default.
• W2012808596 countsByYear W20128085962014 @default.
• W2012808596 countsByYear W20128085962015 @default.
• W2012808596 countsByYear W20128085962016 @default.
• W2012808596 countsByYear W20128085962017 @default.
• W2012808596 countsByYear W20128085962018 @default.
• W2012808596 countsByYear W20128085962019 @default.
• W2012808596 countsByYear W20128085962020 @default.
• W2012808596 countsByYear W20128085962022 @default.
• W2012808596 crossrefType "journal-article" @default.
• W2012808596 hasAuthorship W2012808596A5017367890 @default.
• W2012808596 hasAuthorship W2012808596A5018939455 @default.
• W2012808596 hasAuthorship W2012808596A5025288612 @default.
• W2012808596 hasAuthorship W2012808596A5032700341 @default.
• W2012808596 hasAuthorship W2012808596A5071720008 @default.
• W2012808596 hasAuthorship W2012808596A5074845542 @default.
• W2012808596 hasAuthorship W2012808596A5075840216 @default.
• W2012808596 hasAuthorship W2012808596A5087936561 @default.
• W2012808596 hasConcept C104317684 @default.
• W2012808596 hasConcept C111113717 @default.
• W2012808596 hasConcept C112705442 @default.
• W2012808596 hasConcept C126322002 @default.
• W2012808596 hasConcept C185592680 @default.
• W2012808596 hasConcept C2778461978 @default.
• W2012808596 hasConcept C2778495000 @default.
• W2012808596 hasConcept C2778904437 @default.
• W2012808596 hasConcept C2909962599 @default.
• W2012808596 hasConcept C55493867 @default.
• W2012808596 hasConcept C71924100 @default.
• W2012808596 hasConcept C90924648 @default.
• W2012808596 hasConcept C98274493 @default.
• W2012808596 hasConceptScore W2012808596C104317684 @default.
• W2012808596 hasConceptScore W2012808596C111113717 @default.
• W2012808596 hasConceptScore W2012808596C112705442 @default.
• W2012808596 hasConceptScore W2012808596C126322002 @default.
• W2012808596 hasConceptScore W2012808596C185592680 @default.
• W2012808596 hasConceptScore W2012808596C2778461978 @default.
• W2012808596 hasConceptScore W2012808596C2778495000 @default.
• W2012808596 hasConceptScore W2012808596C2778904437 @default.
• W2012808596 hasConceptScore W2012808596C2909962599 @default.
• W2012808596 hasConceptScore W2012808596C55493867 @default.
• W2012808596 hasConceptScore W2012808596C71924100 @default.
• W2012808596 hasConceptScore W2012808596C90924648 @default.
• W2012808596 hasConceptScore W2012808596C98274493 @default.
• W2012808596 hasIssue "4" @default.
• W2012808596 hasLocation W20128085961 @default.
• W2012808596 hasLocation W20128085962 @default.
• W2012808596 hasOpenAccess W2012808596 @default.
• W2012808596 hasPrimaryLocation W20128085961 @default.
• W2012808596 hasRelatedWork W1863179659 @default.
• W2012808596 hasRelatedWork W2012116840 @default.
• W2012808596 hasRelatedWork W2079819487 @default.
• W2012808596 hasRelatedWork W2102544631 @default.
• W2012808596 hasRelatedWork W2140466909 @default.
• W2012808596 hasRelatedWork W2149933525 @default.

• next